Januvia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Conditions:   Bone Marrow Transplant Complications;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia, Adult;   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia Interventions:   Drug: Sitagliptin;   Drug: Bortezomib;   Drug: Cyclophosphamide Sponsor:   Sherif S. Farag Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials